Days after PG treatment with indicated doses. 26105 LLC cells were intravenously injected into sex-matched C57/BL6 mice by tail vein, 14 days later, mice were treated with PBS or PG for 10 days, at day 25, the lungs were removed. (B) Lung tumor multiplicity and maximal tumor sizes were determined as in Figure 1B. Results are mean 6 SEM, n = 5, significant difference, * p,0.05. doi:10.1371/journal.pone.0052117.gGeneration of Lung Cancer Model in Mice and Treatment of CDA-2 and PGA lung cancer metastasis model in C57BL/6 mice was generated by intravenous injection of LLC cells. Briefly, subconfluent LLC cells or A549 cells were harvested and passed through a 40 mm cell strainer (BD Biosciences, Bedford, MA, USA), washed three times with PBS, resuspended in serum free DMEM and injected at a concentration of 26105 LLC cells per mouse into the tail vein. After14 days, mice were injected intraperitoneally (i.p.) with 500 mg/kg, 1000 mg/kg, and 2000 mg/kg CDA-(kindly supplied by Ever Life Pharmaceutical Co. Ltd. Hefei, Anhui, China) or 200 mg/kg, 400 mg/kg, and 800 mg/kg PG (Sigma Aldrich, Steinheim, Germany) in PBS or PBS alone once everyday for 10 days.Evaluation of Lung TumorsAt designated time points, mice were killed, and their lungs were removed, purchase FCCP weighed, and histologically examined. Some mice were kept until death and survival data were obtained. Lung tumour nodules were microdissected using an 18 G needle underCDA-2 Inhibits Lung Cancer DevelopmentFigure 3. CDA-2 blocks tumor proliferation, enhances tumor apoptosis. (A) Tumor bearing mice were treated by 2000 mg/kg CDA-2 or 800 mg/kg PG for 5 days, and lungs were removed, fixed and paraffin embedded. Paraffin-embedded tumor-bearing lung sections were examined by immunostaining with anti-Ki-67-antibodies to 18297096 detect proliferating cells. Bar = 100 mm. Results are means 6 SEM, n = 5, significant difference,* p,0.05. (B) Apoptotic cells were identified by TUNEL staining. Bar = 200 mm. (C) Excised lung tumors were analyzed for the expression of indicated proliferative and apoptotic proteins by immunoblot analysis. The expression of b-actin was used as internal control for the amount of proteins. doi:10.1371/journal.pone.0052117.ga microscope for ML-281 protein analysis. Tumor multiplicity and maximal sizes were determining as described [9]. In brief, whole tumor-bearing lungs were manually inflated with and fixed in 4 paraformaldehyde and embedded. Paraffin-embedded lungs were serially sectioned at 350 mm and histologically examined with hematoxylin and eosin (H E).value was calculated as the percentage of Ki-67 or TUNELpositive tumor cells.Western BlottingLung tumor nodules were carefully microdissected using an 18 G needle from lungs under a microscope. For total protein isolation, 10 mg tumor nodule were homogenized in the 500 ml cell lysis buffer (Cell Signalling Technology, Danvers, MA, USA) containing 5 mM PMSF and protease inhibitors using rotor-stator homogenizer. Western blot analysis was performed as described earlier [13]. Briefly, total protein extracts were loaded on 10 SDS-polyacrylamide gels, subjected to electrophoresis, and blotted onto Hybond-C Extra membranes (Amersham Bioscience, Buckinghamshire, United Kingdom). The primary antibodies included: mouse anti-Bcl-XL, mouse anti-Bcl-2 (both from Santa Cruz Biotechnology, Santa Cruz, CA, USA); mouse anti-PCNA, rabbit anti-cIAP1, rabbit anti-Survivin (all three from Abcam, Cambridge, UK); mouse anti-b-actin (Sigma Aldrich, Steinheim.Days after PG treatment with indicated doses. 26105 LLC cells were intravenously injected into sex-matched C57/BL6 mice by tail vein, 14 days later, mice were treated with PBS or PG for 10 days, at day 25, the lungs were removed. (B) Lung tumor multiplicity and maximal tumor sizes were determined as in Figure 1B. Results are mean 6 SEM, n = 5, significant difference, * p,0.05. doi:10.1371/journal.pone.0052117.gGeneration of Lung Cancer Model in Mice and Treatment of CDA-2 and PGA lung cancer metastasis model in C57BL/6 mice was generated by intravenous injection of LLC cells. Briefly, subconfluent LLC cells or A549 cells were harvested and passed through a 40 mm cell strainer (BD Biosciences, Bedford, MA, USA), washed three times with PBS, resuspended in serum free DMEM and injected at a concentration of 26105 LLC cells per mouse into the tail vein. After14 days, mice were injected intraperitoneally (i.p.) with 500 mg/kg, 1000 mg/kg, and 2000 mg/kg CDA-(kindly supplied by Ever Life Pharmaceutical Co. Ltd. Hefei, Anhui, China) or 200 mg/kg, 400 mg/kg, and 800 mg/kg PG (Sigma Aldrich, Steinheim, Germany) in PBS or PBS alone once everyday for 10 days.Evaluation of Lung TumorsAt designated time points, mice were killed, and their lungs were removed, weighed, and histologically examined. Some mice were kept until death and survival data were obtained. Lung tumour nodules were microdissected using an 18 G needle underCDA-2 Inhibits Lung Cancer DevelopmentFigure 3. CDA-2 blocks tumor proliferation, enhances tumor apoptosis. (A) Tumor bearing mice were treated by 2000 mg/kg CDA-2 or 800 mg/kg PG for 5 days, and lungs were removed, fixed and paraffin embedded. Paraffin-embedded tumor-bearing lung sections were examined by immunostaining with anti-Ki-67-antibodies to 18297096 detect proliferating cells. Bar = 100 mm. Results are means 6 SEM, n = 5, significant difference,* p,0.05. (B) Apoptotic cells were identified by TUNEL staining. Bar = 200 mm. (C) Excised lung tumors were analyzed for the expression of indicated proliferative and apoptotic proteins by immunoblot analysis. The expression of b-actin was used as internal control for the amount of proteins. doi:10.1371/journal.pone.0052117.ga microscope for protein analysis. Tumor multiplicity and maximal sizes were determining as described [9]. In brief, whole tumor-bearing lungs were manually inflated with and fixed in 4 paraformaldehyde and embedded. Paraffin-embedded lungs were serially sectioned at 350 mm and histologically examined with hematoxylin and eosin (H E).value was calculated as the percentage of Ki-67 or TUNELpositive tumor cells.Western BlottingLung tumor nodules were carefully microdissected using an 18 G needle from lungs under a microscope. For total protein isolation, 10 mg tumor nodule were homogenized in the 500 ml cell lysis buffer (Cell Signalling Technology, Danvers, MA, USA) containing 5 mM PMSF and protease inhibitors using rotor-stator homogenizer. Western blot analysis was performed as described earlier [13]. Briefly, total protein extracts were loaded on 10 SDS-polyacrylamide gels, subjected to electrophoresis, and blotted onto Hybond-C Extra membranes (Amersham Bioscience, Buckinghamshire, United Kingdom). The primary antibodies included: mouse anti-Bcl-XL, mouse anti-Bcl-2 (both from Santa Cruz Biotechnology, Santa Cruz, CA, USA); mouse anti-PCNA, rabbit anti-cIAP1, rabbit anti-Survivin (all three from Abcam, Cambridge, UK); mouse anti-b-actin (Sigma Aldrich, Steinheim.
